

Sun Pharma (Netherlands) B.V.
Amsterdam

Annual Report
For the year
ended 31 March 2018

Entry number in the trade register of the Dutch Chamber of Commerce : 33254757

| Table of Contents | Page |
|--|-------------|
| Financial Statements | |
| Balance Sheet as at 31 March 2018 | 3 |
| Profit and loss account for the year ended 31 March 2018 | 4 |
| Notes to the Financial Statements | 5-14 |
| Other Information | 15 |
| Independent auditor's Report | 16 |

Sun Pharma (Netherlands) B.V.

Balance sheet as at 31 March 2018

(After appropriation of the results)

(Amounts in US Dollars)

| | Notes | As at 31 March 2018 | As at 31 March 2017 |
|--|-------|------------------------|------------------------|
| Fixed Assets | | | |
| Financial fixed assets | | | |
| Investments | 1 | 635,201,118 | 617,402,448 |
| Amount owed by group entities | 2 | 146,680,385 | 87,184,238 |
| Total fixed assets | | 781,881,503 | 704,586,686 |
| Current assets (due within one year) | | | |
| Amount owed by group entities | 2 | 5,438,477 | 54,407,078 |
| Other receivables | 3 | 1,849,038 | 3,727,977 |
| Cash at banks | 4 | 31,993,756 | 56,736,933 |
| Total current assets | | 39,281,271 | 114,871,988 |
| Current liabilities (due within one year) | | | |
| Accrued liabilities and other payables | 5 | 10,173,375 | 1,171,395 |
| Total current liabilities | | 10,173,375 | 1,171,395 |
| Total assets less liabilities | | 810,989,399 | 818,287,279 |
| Shareholder's Equity | | | |
| Share capital | 6 | 678,258,176 | 584,883,522 |
| Share premium reserve | | 155,000,000 | 155,000,000 |
| Retained earnings | | (44,013,576) | (36,715,696) |
| Translation reserve | | 21,744,799 | 115,119,453 |
| Total shareholder's equity | | 810,989,399 | 818,287,279 |

The accompanying notes form an integral part of these financial statements.

Sun Pharma (Netherlands) B.V.

Profit and loss for the year ended 31 March 2018

(Amounts in US Dollars)

| | Notes | As at 31 March 2018 | As at 31 March 2017 |
|--|-------|------------------------|------------------------|
| Holding activities | | | |
| Dividend from investments | 7 | 2,364,220 | 8,273,044 |
| Profit on disposal of subsidiary | | - | 5,363,805 |
| Excess provision w/back | | - | 10,846 |
| Impairment in value of investments | | - | (5,415,000) |
| Result from holding activities | | 2,364,220 | 8,232,695 |
| Financing activities | | | |
| Interest income on amount owed by group entities | 8 | 7,779,109 | 4,896,041 |
| Interest income from banks & others | | 625,985 | 1,160,197 |
| Impairment of receivable from group entities | 2 | (21,587,800) | - |
| Result from financing activities | | (13,182,706) | 6,056,238 |
| Other financial income and expenses | 9 | 3,604,827 | 6,003,503 |
| Other expenses | | 3,604,827 | 6,003,503 |
| General and administration expenses | 10 | (265,067) | (1,364,479) |
| Total expenses | | (265,067) | (1,364,479) |
| Result before taxation | | (7,478,726) | 18,927,957 |
| Corporate income tax | 11 | (1,471,033) | 20,207 |
| Result after taxation | | (8,949,759) | 18,948,164 |
| Other comprehensive results | | | |
| Revaluation securities | | 1,651,879 | - |
| Total after comprehensive results | | (7,297,880) | 18,948,164 |

The accompanying notes form an integral part of these financial statements.

Sun Pharma (Netherlands) B.V.

Notes to the financial statements

General:

Sun Pharma (Netherlands) B.V. ("the Company") was incorporated as a limited liability company under the laws of the Netherlands on 14 December 1993 and has its statutory seat in Hoofddorp, the Registered Office address is Polarisavenue 87, 2132 JH Hoofddorp, The Netherlands. The Company name has been changed from Ranbaxy (Netherlands) B.V. to Sun Pharma (Netherlands) B.V. effective from 21st July 2017.

The functional and reporting currency of Sun Pharma (Netherlands) B.V. is US Dollar, mainly based on the nature of the Company and in accordance with the primary economic environment in which the company operates as a holding company within the sun Group.

Financial reporting period

The current financial reporting period is for the 12 months ending 31 March 2018.

Basis of presentation:

The financial statements have been prepared in accordance with Title 9, Book 2 of the Netherlands Civil Code.

Going concern

These financial statements have been prepared on the basis of the going concern assumption.

Accounting policies

a. General

The principles applied for the valuation of assets and liabilities and result determination are based on the historical cost convention.

Unless stated otherwise, assets and liabilities are shown at nominal value.

An asset is disclosed in the balance sheet when it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the cost of the asset can be measured reliably. A liability is recognized in the balance sheet when it is expected to result in an outflow from the entity of resources embodying economic benefits and the amount of the obligation can be measured with sufficient reliability.

If a transaction results in a transfer of future economic benefits and or when all risks relating to assets or liabilities to a third party, the asset or liability is no longer included in the balance sheet. Assets and liabilities are not included in the balance sheet if economic benefits are not probable and/or cannot be measured with sufficient reliability.

Revenues and expenses are allocated to the period to which they relate. Revenues are recognized when the right to receive the revenues is established.

The financial statements are presented in U.S. Dollars, the company's functional currency. All financial information in U.S. Dollars has been rounded to the nearest Dollar.

b. Using estimates and judgements

The preparation of the financial statements requires that management make judgements and use estimates and assumptions that affect the application of the accounting principles and the reported value of the assets and liabilities and the income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are continually reviewed. Revised estimates are stated in the period in which the estimate is revised and in future periods for which the revision has consequences.

The accounting policies regarding fixed financial asset valuation and valuation of financial instruments are in the opinion of management the most critical for the purpose of presenting the financial position and require estimates and assumption.

c. Financial Fixed Assets

Financial fixed assets mainly consists of participations in group entities. For accounting policies relating to amounts held with group entities, refer to Financial Instruments policy. The participations are accounted for by the cost method and are stated at cost, less any provision for other than temporary decline in value.

Financial fixed assets are tested for impairment in the case of changes, or circumstances arising, that lead to an indication that the carrying amount of the asset will not be recovered. The recoverability of assets in use is determined by comparing the carrying amount of an asset with the estimated present value of the future net cash flows which the asset is expected to generate. If the carrying amount of an asset exceeds the estimated present value of the future cash flows, impairment is charged to statement of profit and loss account as the difference between the carrying amount and the recoverable amount.

d. Impairment of financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset, with negative impact on the estimated future cash flows of that asset, which can be estimated reliably.

Objective evidence that financial assets are impaired includes default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy, adverse changes in the payment status of borrowers or issuers, indications that a debtor or issuer is approaching bankruptcy, or the disappearance of an active market for a security.

The entity considers evidence of impairment for financial assets measured at amortised cost (loan and receivables and financial assets that are held to maturity) at both a specific asset and collective level. All individually significant assets are assessed for specific impairment. Those individually significant assets found not to be specifically impaired and assets that are not individually significant are then collectively assessed for impairment by grouping together assets with similar risk characteristics.

An impairment loss in respect of a financial asset stated at amortised cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate for Investments carried at cost the cash flows are discounted at the Investments weighted average cost of capital taking into account specific entity, industry and country risks.

Losses are recognised in the profit and loss account and reflected in an allowance account against loans and receivables or investment securities held to maturity. Interest on the impaired asset continues to be recognised by using the asset's original effective interest rate.

When, in a subsequent period, the amount of an impairment loss decreases, and the decrease can be related objectively to an event occurring after the impairment was recognised, the decrease in impairment loss is reversed through profit or loss (up to the amount of the original cost).

e. Financial instruments

Financial instruments include amounts owed by group entities, other receivables, accrued liabilities and other payables, short term bank borrowings and amounts owed to group entities. Financial instruments are initially recognised at fair value. After initial recognition, financial instruments are valued at amortized cost on the basis of the effective interest method, less impairment losses.

f. Shareholders Equity

Financial instruments taking the legal form of shareholders' equity instruments are presented under shareholders' equity. Distributions to the holders of these instruments are deducted from shareholders' equity after deduction of any related benefit related to tax on profit.

Financial instruments taking the legal form of a financial obligation are presented under loan capital. Interest, dividends, income and expenses related to these financial instruments are taken to the profit and loss account.

g. Principles for the translation of foreign currency

Transactions in foreign currencies

Transactions denominated in foreign currency are translated into the relevant functional currency of the group companies at the exchange rate applying on the transaction date. Monetary assets and liabilities denominated in foreign currency are translated at the balance sheet date into the functional currency at the exchange rate applying on that date. Translation gains and losses are taken to the profit and loss account as expenditure. Non-monetary assets and liabilities in foreign currency that are stated at historical cost are translated into U.S. Dollars at the applicable exchange rates applying on the transaction date. Non-monetary assets and liabilities in foreign currency that are stated at present value are translated into U.S. Dollars at the applicable exchange rates at the moment the present value is determined. Translation gains and losses are taken directly to equity as part of the revaluation reserve.

h. Consolidation

In accordance with article 408, Book 2 of the Dutch Civil Code, the Company is not required to prepare consolidated annual accounts in conformity with accounting principles generally accepted in the Netherlands. The annual accounts of the Company and its subsidiaries are included in the consolidated accounts of the holding company, which are available at the Company's registered office and will be filed at Dutch Chamber of Commerce.

i. Recognition of income

Dividend from investments are recorded as income (net of taxes) when the right to receive the income is established. Other income and expenses are recognised and reported on an accrual basis. Interest income is recognised on a time proportion basis taking into account the amount outstanding and the interest rate applicable.

j. Corporate Income tax

Provisions for taxation have been made in accordance with standard ruling practice for holding companies in The Netherlands. Corporate income tax comprises the current and deferred corporate income tax payable and deductible for the reporting period. Corporate income tax is recognised in the statement of profit and loss account except to the extent that it relates to items recognised directly to equity, in which case it is recognised in equity. Current tax comprises the expected tax payable of receivable on the taxable profit or loss for the financial year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to the tax payable in respect of previous years. Deferred tax is provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Sun Pharma (Netherlands) B.V.

Notes to the financial statements for the year ended 31 March 2018 (Continued)

| | | | As at 31 March 2018 | As at 31 March 2017 |
|---|-----------------|---|------------------------|------------------------|
| | | | USD | USD |
| Balance sheet | | | | |
| 1 Investments | | | | |
| <i>Interests in group entities</i> | | | | |
| <u>Name</u> | <u>Domicile</u> | <u>Effective shareholding (%)</u> <u>Current year (Prior period)</u> | | |
| Sun Pharma AZN Pty Ltd (formerly known as Ranbaxy Australia Pty. Ltd) | Australia | 100 (100) | 13,866,307 | 13,866,307 |
| Ranbaxy Farmaceutica Ltda, Brazil | Brazil | 100 (100) | 12,491,730 | 12,491,730 |
| Ranbaxy Pharmaceutical Canada Inc | Canada | 100 (100) | 1,855,487 | 1,855,487 |
| Sun Pharma Egypt Limited (L.L.C.) (formerly known as Ranbaxy Egypt (L.L.C)) | Egypt | 99.90 (99.90) | 13,321,255 | 11,321,255 |
| Ranbaxy Pharmacia Generiques SAS | France | 3.33 (3.33) | 3,252,483 | 3,252,483 |
| Basics GmbH | Germany | 100 (100) | 6,984,012 | 6,984,012 |
| Ranbaxy Ireland Ltd | Ireland | 100 (100) | 13,429,581 | 13,429,581 |
| Ranbaxy Italia S.p.A. | Italy | 100 (100) | 29,051,792 | 29,051,792 |
| Ranbaxy Malaysia Sdn. Bhd. | Malaysia | 50.87 (31.35) | 2,664,438 | 1,015,454 |
| Ranbaxy Pharmaceuticals Ukraine | Ukraine | 99 (99) | 4,950,000 | 4,950,000 |
| Ranbaxy Nigeria Ltd | Nigeria | 52.63 (52.63) | 561,927 | 561,927 |
| Sun Pharmaceutical Industries S.A.C. | Peru | 100 (100) | 1,512,500 | 1,512,500 |
| Ranbaxy (Poland) Sp. Zoo | Poland | 99.98 (99.98) | 1,324,634 | 1,324,634 |
| S.C. Terapia S.A. | Romania | 96.7 (96.7) | 326,716,541 | 326,716,541 |
| AO Ranbaxy | Russia | 99 (99) | 4,229,061 | 4,229,061 |
| Ranbaxy (S.A) (Proprietary) Ltd | South Africa | 100 (100) | 3,272,000 | 3,272,000 |
| Ranbaxy Pharmaceuticals (Pty) Ltd. | South Africa | 100 (100) | 91,672,094 | 91,672,094 |
| Laboratories Ranbaxy S.L. | Spain | 100 (100) | 10,889,738 | 10,889,738 |
| Ranbaxy Thailand Co. Limited | Thailand | 100 (100) | 3,328,661 | 3,328,661 |
| Ranbaxy Holdings(UK) Ltd | United Kingdom | 100 (100) | 54,178,491 | 54,178,491 |
| JSC Biosintez | Russia | 85.1(Nil) | 22,006,056 | 21,508,283 |
| Ranbaxy (UK) Ltd | United Kingdom | 100 (100) | 39,475,267 | 39,475,267 |
| Sun Pharmaceuticals Morocco LLC | Morocco | 100 (100) | 1,496,923 | 1,496,923 |
| | | | 662,530,978 | 658,384,221 |
| <u>Less: Provision for diminution in value of investments</u> | | | | |
| Ranbaxy (UK) Ltd | | | 1,750,000 | 1,750,000 |
| Sun Pharmaceutical Industries S.A.C. | | | 1,512,500 | 1,512,500 |
| Ranbaxy Pharmacia Generiques SAS | | | 3,252,483 | 3,252,483 |
| Ranbaxy Ireland Ltd | | | 5,415,000 | 5,415,000 |
| Ranbaxy Italia S.p.A. | | | 29,051,790 | 29,051,790 |
| | | | 40,981,773 | 40,981,773 |
| Total investments in group entities | | | 621,549,205 | 617,402,448 |
| In the current financial year the Company has converted the subordinated loan given to Sun Pharma Egypt Limited (L.L.C.) amounted to USD 2,000,000 (2016-17 USD 10,302,000) into equity capital. During the year the Company has purchased additional 1,562,163 shares amounted to RM 6701679.27 of Ranbaxy Malaysia Sdn. Bhd. | | | | |
| Furthermore, the Company has converted the receivable from JSC Biosintez amounted to RUB 29 Million into equity. | | | | |
| Other investments | | | | |
| Krystel Biotech Inc. @ | | | 9,223,340 | - |
| SC Pharmaceuticals Inc. # | | | 4,428,573 | - |
| | | | 13,651,913 | - |
| Total Investments | | | 635,201,118 | 617,402,448 |

@ On 7 August 2017 the Company has made investment in Krystel Biotech Inc. of 203,135 shares at a cost of USD 7,000,032. At year end the fair value of Krystel Biotech Inc. amounted USD 9,223,340.

On 21 November 2017 the Company has made investment in SC Pharmaceuticals Inc. of 357,143 shares at a cost of USD 5,000,002. At year end the fair value of SC Pharmaceuticals Inc. amounted USD 4,428,573.

The Company has made use of article 408, Book 2 of the Dutch Civil Code, which enables departure from consolidation of subsidiaries.

Sun Pharma (Netherlands) B.V.

Notes to the financial statements for the year ended 31 March 2018 (Continued)

| | Interest Rate | As at | | As at | |
|--|---------------------------|------------------|--------------------|-------------------|-------------------|
| | | 31 March 2018 | | 31 March 2017 | |
| | | USD | | USD | |
| 2 Amount owed by group entities | | Current | Non-current | Current | Non-current |
| Ranbaxy Holdings (UK) Limited | * | | - | | 92,000 |
| Sun Pharma AZN Pty Ltd (formerly known as Ranbaxy Australia Pty. Ltd) | 2.60% | - | 11,228,744 | - | 11,202,032 |
| Ranbaxy Pharmaceuticals (Pty) Ltd. | 8.50% | 1,755,556 | 17,766,256 | 1,310,403 | 14,726,386 |
| AO Ranbaxy | 6 M USD LIBOR + 250bp | 63,502 | 5,873,173 | 242,970 | 6,941,132 |
| Ranbaxy South Africa | 8.50% | 1,109,617 | 11,895,539 | 845,790 | 9,752,650 |
| Ranbaxy UK Ltd | * | - | 12,817,586 | - | 11,052,189 |
| Ranbaxy Farmaceuticals Ltda | 6 M USD LIBOR + 250 bp | 809,999 | 20,124,763 | 124,763 | 20,000,000 |
| Ranbaxy Nigeria Limited | 6 M USD LIBOR + 300bp | 364,100 | 8,974,233 | 327,747 | 8,646,488 |
| Sonke Pharmaceuticals | 8.50% | - | - | 59,546 | 186,314 |
| Ranbaxy Pharmacia Generiques SAS | ** 6 M Euro LIBOR + 150bp | - | - | - | - |
| Sun Pharmaceuticals Industries INC | | - | - | - | - |
| Sun Pharmaceuticals Morocco LLC | 3 M USD LIBOR + 250bp | 158,152 | 4,930,131 | 430,131 | 4,500,000 |
| Sun Pharma Egypt Limited (L.L.C.) (formerly known as Ranbaxy Egypt (L.L.C)) | | - | 227,767 | 142,718 | 85,049 |
| Ranbaxy Italia S.p.A. | ** 6 M Euro LIBOR + 125bp | - | - | - | - |
| JSC Biosintez | 7.50% | 1,177,551 | 52,842,193 | 50,923,010 | - |
| | | 5,438,477 | 146,680,385 | 54,407,078 | 87,184,238 |

* Interest free loans

** A provision for doubtful debts of USD 21,587,800 has been recognised at 31 March 2018 on the basis of recoverable assessment the provision consists of USD 16,785,400 Loan to Ranbaxy Pharmacia Generiques SAS and USD 4,802,400 Ranbaxy Italia S.p.A.

Sun Pharma (Netherlands) B.V.

Notes to the financial statements for the year ended 31 March 2018 (Continued)

| | As at 31 March 2018 | As at 31 March 2017 |
|--|------------------------|------------------------|
| | USD | USD |
| 3 Other receivables | | |
| Withholding taxes | 549,886 | 356,250 |
| VAT | 7,082 | 7,639 |
| Other loans | 80,000 | 80,000 |
| Bank interest receivable | 52,705 | 340,166 |
| Other Assets | 1,159,365 | 2,943,921 |
| | 1,849,038 | 3,727,977 |
| Other assets | | |
| Interest on Escrow a/c * | 308,525 | 90,884 |
| Insurance premium - receivable from entities | 8,345 | 36,451 |
| Receivable from Biotech - Investment | - | 2,087,766 |
| Bank fee and charges receivable from JSC Biosintez | 435,839 | 435,839 |
| Interest outstanding to SBER bank receivable from JSC Biosintez | 189,850 | 195,031 |
| Dividend receivable from Nigeria | 15,480 | 15,455 |
| Third party payment receivable from Nigeria | 201,326 | 82,495 |
| | 1,159,365 | 2,943,921 |
| * Pivable to Biotech Inc. | | |
| 4 Cash at Banks | | |
| Current account with Canara Bank (USD) | 1,570,136 | 1,003,300 |
| Current account with Canara Bank (EUR) | 18,065 | 2,287,352 |
| Current account with Canara Bank (GBP) | 2,367,309 | 5,803 |
| Current account with SBER Bank SA (USD) | 39,922 | 39,922 |
| Current account with SBER Bank SA (RUB) | 2,524,593 | 5,138,106 |
| On deposit accounts : | | |
| - Fixed deposit with SBER Bank (RUB) with original maturity of three or less than 3 months | 3,473,731 | - |
| - Fixed deposit with Canara Bank (USD) with original maturity of three or less than 3 months | 22,000,000 | - |
| - Fixed deposit with Canara Bank (USD) with original maturity over 12 months | - | 48,262,450 |
| | 31,993,756 | 56,736,933 |
| Cash at banks & deposits is not restricted and is freely distributable. | | |
| 5 Accrued liabilities and other payables | | |
| Accruals | 31,891 | 29,932 |
| Other liabilities | 8,670,451 | 1,141,463 |
| Provision for tax | 1,471,033 | - |
| | 10,173,375 | 1,171,395 |
| Accruals | | |
| Audit fee | 31,891 | 29,932 |
| | 31,891 | 29,932 |
| Other liabilities | | |
| Advance from Ranbaxy Ireland Ltd | 8,054,822 | - |
| Insurance amount payable to entities | 50,579 | 50,579 |
| Interest on Escrow a/c payable to Biotech Inc. | 308,525 | 90,884 |
| Law firm fee | 256,525 | 1,000,000 |
| | 8,670,451 | 1,141,463 |

During the year the Company has received advance from Ranbaxy Ireland Limited amounted to EURO 6,500,000

6 Shareholder's equity

The Authorized share capital of the Company amounts to EUR 1,750,000,000 divided into 17,500,000 shares of EUR 100 each. Issued and paid up shares are 5,473,340 (Previous year 5,473,340) shares of EUR 100 each.

| | Share capital | Share Premium reserve | Retained Earnings | Translation reserve | In USD Total |
|---------------------------------------|--------------------|-----------------------|---------------------|---------------------|--------------------|
| Balance as on 01.04.16 | 621,829,210 | 155,000,000 | (55,663,860) | 78,173,765 | 799,339,115 |
| Additions made during the period | - | - | - | - | - |
| Dividend paid during the period | - | - | - | - | - |
| Translation adjustment for the period | (36,945,688) | - | - | 36,945,688 | - |
| Result for the period | - | - | 18,948,164 | - | 18,948,164 |
| Balance as on 31.03.17 | 584,883,522 | 155,000,000 | (36,715,696) | 115,119,453 | 818,287,279 |
| Balance as on 01.04.17 | 584,883,522 | 155,000,000 | (36,715,696) | 115,119,453 | 818,287,279 |
| Additions made during the period | - | - | - | - | - |
| Comprehensive income | - | - | - | - | - |
| Dividend paid during the period | - | - | - | - | - |
| Translation adjustment for the period | 93,374,654 | - | - | (93,374,654) | - |
| Result for the period | - | - | (7,297,880) | - | (7,297,880) |
| Balance as on 31.03.2018 | 678,258,176 | 155,000,000 | (44,013,576) | 21,744,799 | 810,989,399 |

Note:

Translation reserve includes translation of share capital translated from EURO to USD at closing exchange rate. The EURO to USD exchange rate used as per 31 March 2018 is 1.2392 (2016-17: 1.0686)

Appropriation of result

In anticipation of a resolution being passed to that effect at the general meeting to be held to consider and adopt the financial statements for the year ended 31 March 2018, loss for the year of US Dollars 8,949,759 has been added to retained earnings brought forward from previous years.

Sun Pharma (Netherlands) B.V.

Notes to the financial statements for the year ended 31 March 2018 (Continued)

| | As at 31 March 2018 USD | As at 31 March 2017 USD |
|---|-------------------------------|-------------------------------|
| 7 Dividend from investments | | |
| Ranbaxy Ireland Limited, Ireland | - | 8,256,148 |
| Ranbaxy Nigeria Ltd | - | 16,896 |
| Ranbaxy Holding UK Ltd | 2,364,220 | - |
| | <u>2,364,220</u> | <u>8,273,044</u> |
| 8 Interest income on amount owed by group entities | | |
| Ranbaxy Nigeria Limited, Nigeria | 364,100 | 327,747 |
| Laboratorios Ranbaxy S.L., Spain | - | 68,114 |
| Ranbaxy South Africa Proprietary Limited, South Africa | 807,685 | 731,549 |
| Ranbaxy Farmaceutica Ltda., Brazil | 809,999 | 709,858 |
| Ranbaxy Pharmaceuticals (Pty) Ltd. | 1,076,916 | 975,399 |
| AO Ranbaxy, Russia | 270,685 | 242,971 |
| Sonke Pharmaceuticals (Proprietary) Ltd., South Africa | - | 37,532 |
| Sun Pharmaceuticals Morocco | 175,724 | 149,507 |
| Sun Pharma Egypt Ltd. (L.L.C. (formerly Ranbaxy Egypt (L.L.C.), Egypt | - | 142,718 |
| Sun Pharma AZN Pty Ltd (formerly known as Ranbaxy Australia Pty. Ltd) | 299,100 | 518,214 |
| Sun Pharmaceutical Industries INC | 191,239 | - |
| JSC Biosintez | 3,783,661 | 992,432 |
| | <u>7,779,109</u> | <u>4,896,041</u> |
| 9 Other financial income and expenses | | |
| Currency exchange rate differences | 3,604,827 | 6,003,503 |
| Total other financial income and expenses | <u>3,604,827</u> | <u>6,003,503</u> |

Sun Pharma (Netherlands) B.V.

Notes to the financial statements for the year ended 31 March 2018 (Continued)

| | As at 31 March 2018 USD | As at 31 March 2017 USD |
|---|-------------------------------|-------------------------------|
| 10 General and administrative expenses | | |
| Audit fee | 40,417 | 33,547 |
| Legal fee | 105,004 | 1,059,705 |
| Consultancy charges | 112,491 | 63,357 |
| General expenses | - | 204,933 |
| Bank charges | 7,155 | 2,937 |
| | <u>265,067</u> | <u>1,364,479</u> |
| 11 Corporate income tax | | |
| Current tax | 1,471,033 | - |
| Correction prior years | - | 20,207 |
| Current tax Previous year | - | - |
| | <u>1,471,033</u> | <u>20,207</u> |

On the basis of the (Loss)/Profit results before taxation of USD (7,478,726) (2016-17: USD 18,927,957), the effective corporate income tax rate would be 2% (2016-17: 2%).

The corporate income tax rates in 2017-18 and 2016-17 were 20% for profits up to and including EUR 200,000 and 25% for profits exceeding EUR 200,000.

| | As at 31 March 2018 | As at 31 March 2017 |
|---|------------------------|------------------------|
| Results before taxation | (7,478,726) | 18,927,957 |
| Tax adjustments | 17,620,328 | (7,798,121) |
| Taxable profit | 10,141,602 | 11,129,837 |
| Compensation | (4,217,470) | (11,129,837) |
| Taxation thereon, based on corporate income tax rates | <u>1,471,033</u> | <u>-</u> |

Effective tax rate is lower than the prevailing tax rates in the Netherlands due to some of the income being non-taxable in nature e.g. dividend received, gain/loss on account of disposals of participations, unrealized gains/losses on foreign currency loans and advances to subsidiaries etc.

12 Staff member and employment cost

The Company has no employees and hence incurred no wages, salaries or related social security charges for the year ended 31 March 2018 (2016-17: Nil).

13 Directors

The Company has three managing directors. During the year, none of the directors has received any remuneration in their capacity as a director. (2016-17: Three)

Sun Pharma (Netherlands) B.V.

Notes to the financial statements for the year ended 31 March 2018 (Continued)

14 Subsequent Events

No events have occurred since balance sheet date, which would change the financial position of the Company and which would require adjustment of or disclosure in the annual accounts now presented.

15 Related parties

Material transactions with related parties primarily involve investments (including related dividend income) and loans receivable (including related interest).

Dated

Amsterdam

Board of Managing Directors

Hellen De Kloet

Prashant Lakhamshi Savla

Harin Parmanand Mehta

Sun Pharma (Netherlands) B.V.


Other Information

Appropriation of results

The management proposes to the shareholder to add the result for the year to the retained earnings.

Independent auditor's opinion

The independent auditor's opinion is set forth on the next page.



Accountants

Zwolsseweg 27
2994 LB Barendrecht
Telefoon 010-242 42 42
Telefax 010-242 42 18
Website www.arep.nl
E-mail Rotterdam@arep.nl

ABN AMRO 49 88 55 295
Iban nr. NL36 ABNA 049885 5295
Switcode ABN ALL 2A
B T W N L 8 1 2 4 9 9 1 2 8 B 0 1
Beconnummer 276601

To the management board of
Sun Pharma (Netherlands) B.V.
Polarisavenue 87
2132 JH HOOFFDORP

September 3rd, 2018

INDEPENDENT AUDITOR'S REPORT

A. Report on the audit of the financial statements for the year ended March 31, 2018 included in the annual report

Our opinion

We have audited the financial statements for the year ended March 31, 2018 of Sun Pharma (Netherlands) B.V., based in Amsterdam.

In our opinion the accompanying financial statements give a true and fair view of the financial position of Sun Pharma (Netherlands) B.V. as at March 31, 2018, and of its result for the year ended March 31, 2018 in accordance with Part 9 of Book 2 of the Dutch Civil Code.

The financial statements comprise:

- 1 the balance sheet as at March 31, 2018;
- 2 the profit and loss account for the year ended at March 31, 2018; and
- 3 the notes comprising a summary of the accounting policies and other explanatory information.

Basis for our opinion


We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. Our responsibilities under those standards are further described in the 'Our responsibilities for the audit of the financial statements' section of our report.

We are independent of Sun Pharma (Netherlands) B.V. in accordance with the Verordening inzake de onafhankelijkheid van accountants bij assurance-opdrachten (ViO, Code of Ethics for Professional Accountants, a regulation with respect to independence) and other relevant independence regulations in the Netherlands. Furthermore we have complied with the Verordening gedrags- en beroepsregels accountants (VGBA, Dutch Code of Ethics).

We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our

B. Report on the other information included in the annual report

In addition to the financial statements and our auditor's report thereon, the annual report contains other information as required by Part 9 of Book 2 of the Dutch Civil Code.



Based on the following procedures performed, we conclude that the other information:

- is consistent with the financial statements and does not contain material misstatements;
- Contains the information as required by Part 9 of Book 2 of the Dutch Civil Code.

We have read the other information. Based on our knowledge and understanding obtained through our audit of the financial statements or otherwise, we have considered whether the other information contains material misstatements

By performing these procedures, we comply with the requirements of Part 9 of Book 2 of the Dutch Civil Code and the Dutch Standard 720. The scope of the procedures performed is substantially less than the scope of those performed in our audit of the financial statements.

C. Description of responsibilities regarding the financial statements

Responsibilities of management for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore, management is responsible for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

As part of the preparation of the financial statements, management is responsible for assessing the company's ability to continue as a going concern. Based on the financial reporting framework mentioned, management should prepare the financial statements using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements


Our objective is to plan and perform the audit assignment in a manner that allows us to obtain sufficient and appropriate audit evidence for our opinion.

Our audit has been performed with a high, but not absolute, level of assurance, which means we may not detect all material errors and fraud during our audit.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. The materiality affects the nature, timing and extent of our audit procedures and the evaluation of the effect of identified misstatements on our opinion.

We have exercised professional judgment and have maintained professional scepticism throughout the audit, in accordance with Dutch Standards on Auditing, ethical requirements and independence requirements. Our audit included e.g.:

- Identifying and assessing the risks of material misstatement of the financial statements, whether due to fraud or error, designing and performing audit procedures responsive to those risks, and obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtaining an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control;
- Evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management,



- Concluding on the appropriateness of management's use of the going concern basis of accounting, and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company to cease to continue as a going concern;
- Evaluating the overall presentation, structure and content of the financial statements, including the disclosures; and
- Evaluating whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Barendrecht, September 3rd, 2018

AREP Rotterdam B.V.

Drs. G. van de Werken RA

RAV2018-050